Akari Logo (1).jpg
Akari Therapeutics Announces Private Placement
July 07, 2021 09:15 ET | Akari Therapeutics Plc
NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to...
Akari Logo (1).jpg
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
June 29, 2021 16:01 ET | Akari Therapeutics Plc
Open Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP) Phase III study of nomacopan in severe...
Akari Logo (1).jpg
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid
April 28, 2021 08:00 ET | Akari Therapeutics Plc
A multicenter Phase III study of nomacopan for the treatment of moderate and severe bullous pemphigoid (BP) has been initiatedNomacopan has potential to replace long term steroid treatment (standard...
Akari Logo (1).jpg
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
April 22, 2021 07:30 ET | Akari Therapeutics Plc
NEW YORK and LONDON, April 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Logo (1).jpg
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
April 20, 2021 18:40 ET | Akari Therapeutics Plc
Opening of Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP), a severe dermatological disease with no...
Akari Logo (1).jpg
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
April 12, 2021 10:16 ET | Akari Therapeutics Plc
FDA investigational new drug application (IND) now open Clinical sites expected to open for recruitment mid-2021 NEW YORK and LONDON, April 12, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc...
Akari Logo (1).jpg
Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma
March 04, 2021 08:30 ET | Akari Therapeutics Plc
NEW YORK and LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Logo (1).jpg
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
February 25, 2021 09:07 ET | Akari Therapeutics Plc
A newly published review article in the journal CELLS highlights the role LTB4 plays in the induction of vascular endothelial growth factor (VEGF) damage and retinal inflammation in the eye. Elevated...
Akari Logo (1).jpg
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease
February 01, 2021 09:29 ET | Akari Therapeutics Plc
Building on the positive clinical and safety data from its lead drug nomacopan, Akari is developing a second related therapeutic candidate (votucalis) focusing on new clinical targets.Votucalis...
Akari Logo (1).jpg
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
January 06, 2021 09:32 ET | Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...